Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer
Recruiting now · Not applicable
Conditions studied: Testicular Cancer, Seminoma, Quality of Life, De-escalation, RPLND
In brief
The goal of this prospective observational study is to learn about the short- and long-term effects of treating men over the age of 18 with good prognosis metastatic testicular cancer with either primary retropertioneal lymph node dissection, RPLND, (for low-stage metastastic seminoma) or three doses of chemotherapy for metastastic seminoma or nonseminoma. The main question it aims to answer is: Does primary RPLND lower the risk of side-effects compared to receiving chemotherapy?
Key facts
- Study ID
- NCT07498959
- Run by
- Sahlgrenska University Hospital
- People needed
- 160
- Starts
- 2026-03-19
- Expected to finish
- 2032-03-25
- Last updated by the study team
- 2026-03-27
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
You may qualify if…
- Patients ≥18 years undergoing an open or minimally invasive primary retroperitoneal lymph node dissection (RPLND) due to seminoma stage II A/B (maximum 2 nodes, <30 mm in any dimension)
- Patients undergoing an open or minimally invasive primary RPLND due to a retroperitoneal relapse of seminoma (maximum 2 nodes, <30 mm in any dimension)
- Patients ≥18 years scheduled for 3-4 courses of chemotherapy due to a newly diagnosed good-prognosis metastatic germ cell tumor (nonseminoma or seminoma)
You may not qualify if…
- Previous chemotherapy (including adjuvant chemotherapy at diagnosis)
- Previous RPLND
- Practical considerations, such as not being able to read and sign informed consent or understand the questionnaires
Where it is running
- Sahlgrenska University Hospital — Gothenburg, Göteborg, Sweden (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.